Milestone
Lens PoS v1 complete
Dual-instrument snapshot prepared.
View Details →Loading…
Snapshot of company progress. No downloads; living record for diligence and internal review.
Dual-instrument snapshot prepared.
View Details →Alpha flows shipped in Figma.
View Source →We successfully launched the Beta version of NeuroLens™ and NeuroTrack™, onboarding initial pilot families.
View Details →Early proof-of-signal data for NeuroLens™ indicates strong sensitivity in ND detection using dual-instrument comparison.
View Details →HMRC has approved Congneva Ltd's SEIS Advance Assurance application, enabling the company to offer tax-efficient investment opportunities to qualifying investors.
View Details →Congneva Ltd has formally submitted its SEIS application to HMRC, marking a key legal and fundraising milestone.
View Source →Successfully closed Series A funding round with leading healthcare VCs.
View Details →NeuroLens™ validation study shows 95% accuracy in early detection.
View Details →FDA pre-submission meeting scheduled for Q2 2025.
View Details →Signed pilot agreement with major NHS Trust for NeuroLens™ deployment.
View Details →Next-generation AI model improves processing speed by 40%.
View Details →Strong Q4 performance with 150% revenue growth year-over-year.
View Details →